# Trilaciclib Combined With Chemotherapy for Perioperative Treatment of Osteosarcoma

> **NCT06217003** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Xinxiang Medical College** · enrollment: 20 (estimated)

## Conditions studied

- Osteosarcoma

## Interventions

- **DRUG:** Trilaciclib

## Key facts

- **NCT ID:** NCT06217003
- **Lead sponsor:** The First Affiliated Hospital of Xinxiang Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-02-01
- **Primary completion:** 2025-02-01
- **Final completion:** 2025-08-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06217003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06217003, "Trilaciclib Combined With Chemotherapy for Perioperative Treatment of Osteosarcoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06217003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*